The settlement removes the existential overhang of patent litigation but at a steep cash cost that consumes nearly all of Liquidia's current cash balance. The key swing factor is whether YUTREPIA's PAH-only revenue can sustain the company through the $145.4 million payments due in early 2027 — monitor Q3 2026 earnings call for updated PAH sales trajectory and any PH-ILD revenue loss quantification.
Price Chart
Executive Summary
Liquidia entered into a global settlement with United Therapeutics (UTC) resolving all six pending lawsuits, including patent infringement, trade secret, and antitrust litigations. Liquidia will pay a net $380.7 million in installments through April 2027, remove the PH-ILD indication from YUTREPIA's label, and cease all PH-ILD promotion, while retaining the right to commercialize YUTREPIA for PAH. The company reported preliminary Q3 2026 YUTREPIA net product sales of $222.7 million and cash of $396.1 million, and expects to fund the settlement from operations without additional financing.
Key Facts
- Liquidia will make a net payment of $175.0 million to UTC within 30 business days, plus $145.4 million in two equal installments due January 31, 2027 and April 30, 2027.
- Liquidia will pay an aggregate of $60.3 million to Sandoz ($21.75 million), Henderson ($19.05 million), and PBM ($19.45 million) to settle interests in the RareGen antitrust litigation.
- Total cash outflows from the settlement are approximately $380.7 million ($175M + $145.4M + $60.3M).
- Liquidia must file with the FDA to remove the PH-ILD indication from YUTREPIA's label and immediately cease all marketing, promotion, and detailing of YUTREPIA for PH-ILD.
- Liquidia reported preliminary Q3 2026 YUTREPIA net product sales of $222.7 million and cash and cash equivalents of $396.1 million as of September 30, 2026.
- The minimum cash covenant under the HCR revenue interest financing agreement was increased from $15.0 million to $45.0 million.
- All six lawsuits between Liquidia and UTC will be dismissed with prejudice, including patent cases, trade secret claims, and antitrust litigation.
- UTC granted a covenant not to sue Liquidia for PAH sales of the non-infringing YUTREPIA product through the term of the agreement.
Financial Impact
Total settlement cash outflows of approximately $380.7 million, representing ~96% of the company's $396.1 million cash balance as of September 30, 2026. The company expects to fund payments from ongoing YUTREPIA sales and cash on hand without additional financing.
Risk Factors
- Removal of PH-ILD indication from YUTREPIA's label eliminates a significant revenue growth vector and may reduce total addressable market.
- Cash balance of $396.1 million is nearly fully consumed by $380.7 million in settlement payments, leaving minimal operating buffer.
- Minimum cash covenant increased from $15M to $45M under the HCR financing agreement, adding financial constraint.
- UTC retains rights to sue Liquidia for any indication other than PAH, including future indications like SSc-RP or PH-COPD.
- The settlement does not cover new treprostinil-containing products or future development programs.
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115672 |
| Document: tm2627557d1_8k.htm | 0001104659-26-115672 |
| Document: tm2627557d1_ex10-2.htm | 0001104659-26-115672 |
| Document: tm2627557d1_ex10-5.htm | 0001104659-26-115672 |
| Document: tm2627557d1_ex10-3.htm | 0001104659-26-115672 |
| Document: tm2627557d1_ex10-4.htm | 0001104659-26-115672 |
| Document: tm2627557d1_ex99-1.htm | 0001104659-26-115672 |
| Document: 0001104659-26-115672-index-headers.html | 0001104659-26-115672 |
| Document: 0001104659-26-115672-index.html | 0001104659-26-115672 |
| Document: 0001104659-26-115672.txt | 0001104659-26-115672 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | 8-K | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Oct 13, 2026 12d ago | Insider Cluster | $33.94 $34.78 | ▲ +2.48% | ▲ +2.19% | $43.74 (+28.87%) |
Sep 30, 2026 26d ago | 8-K | $27.99 $28.64 | ▼ −2.32% | ▼ −1.58% | $43.74 (−56.27%) |
Sep 3, 2026 7w ago | 8-K | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Sep 3, 2026 7w ago | Press Release | $68.63 $68.66 | ▲ +0.04% | ▲ +0.43% | $43.74 (−36.27%) |
Aug 25, 2026 8w ago | Insider Cluster | $71.36 $69.94 | ▼ −1.99% | ▼ −2.65% | $43.74 (−38.71%) |
Aug 21, 2026 9w ago | Insider Cluster | $70.27 $70.49 | ▲ +0.31% | ▼ −0.01% | $43.74 (−37.75%) |
Aug 12, 2026 10w ago | 8-K | $78.79 $72.10 | ▼ −8.49% | ▼ −9.19% | $43.74 (−44.49%) |
Aug 12, 2026 10w ago | Press Release | $78.79 $72.10 | ▲ +8.49% | ▲ +9.19% | $43.74 (+44.49%) |
Jul 29, 2026 12w ago | Insider Cluster | $86.80 $84.11 | ▼ −3.10% | ▼ −3.82% | $43.74 (−49.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers